Table 3 Univariate analysis for progression-free survival
From: Outcome of lung metastases due to bone giant cell tumor initially managed with observation
Variable | No. of patients | 5-year progression-free survival (95% CI) (%) | p value |
|---|---|---|---|
Age (years) | |||
 < 30 | 11 | 36.4 (14.3–66.1) | 0.116 |
 30 ≤ | 11 | 60.6 (29.7–84.8) | |
Sex | |||
 Male | 6 | 88.3 (36.9–97.7) | 0.066 |
 Female | 16 | 32.8 (13.0–61.4) | |
Site | |||
 Distal radius | 5 | 40.0 (10.0–80.0) | 0.926 |
 Other sites | 17 | 52.9 (30.3–74.5) | |
Campanacci classification | |||
 Stage II | 4 | 50.0 (12.3–87.7) | 0.913 |
 Stage III | 18 | 48.6 (26.7–71.0) | |
Previous surgery | |||
 No | 15 | 60.0 (34.8–80.8) | 0.260 |
 Yes | 7 | 28.6 (7.2–67.3) | |
Lung metastasis at presentation | |||
 No | 16 | 56.3 (32.4–77.5) | 0.502 |
 Yes | 6 | 25.0 (3.8–73.8) | |
Pathological fracture at presentation | |||
 No | 16 | 41.7 (20.2–66.9) | 0.187 |
 Yes | 6 | 66.7 (26.8–91.6) | |
Surgery for primary tumor | |||
 Curettage | 6 | 50.0 (16.8–83.2) | 0.769 |
 Resection | 16 | 50.0 (27.3–72.7) | |
Pre- and postoperative denosumab treatment | |||
 No | 18 | 55.6 (33.0–76.0) | 0.376 |
 Yes | 4 | 25.0 (3.4–76.2) | |
Local recurrence | |||
 None | 12 | 41.7 (18.5–69.2) | 0.462 |
 ≥ 1 | 10 | 56.0 (24.7–83.2) | |
Interval between surgery of primary tumor and occurrence of lung metastasis (months) | |||
 < 24 | 13 | 34.6 (13.2–64.8) | 0.399 |
 24 ≤ | 9 | 66.7 (33.3–88.9) | |
Number of nodules | |||
 < 4 | 7 | 57.1 (23.0–85.6) | 0.397 |
 4 ≤ | 9 | 44.4 (17.7–74.9) | |
Lung lesion | |||
 Solitary | 2 | 100.0 | 0.224 |
 Multiple | 20 | 43.8 (23.9–65.8) | |
Laterality | |||
 Unilateral | 3 | 66.7 (15.3–95.7) | 0.617 |
 Bilateral | 19 | 46.1 (25.2–68.3) | |
Size of maximum nodule (mm) | |||
 ≤ 5 | 11 | 63.6 (33.9–85.7) | 0.022* |
 5 < | 5 | 40.0 (10.0–80.0) | |